Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-22

FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approved a supplemental application for ibandronate sodium filed by Aurobindo Pharma Limited, approving the generic product under the ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBANDRONATE SODIUM (ibandronate sodium)

Snippet

SUPPL AP for IBANDRONATE SODIUM (IBANDRONATE SODIUM)